Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI filing briefs · archive

8-K filings in May 2025, explained

1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

1 of 1,080 briefs matches

newest first · times in ET
TNDMTANDEM DIABETES CARE INC May 23, 4:21 PM ET

Tandem Diabetes settles Roche patent disputes for $36 million paid over five years

Neutral legal/regulatory Written later 1.015.07

On May 21, 2025, Tandem Diabetes and Roche entities agreed to settle all patent disputes over the t:slim X2 pump, terminating pending actions before Unified Patent Court divisions in France and Germany. The Tandem entities will pay $36 million over five years, starting with an $8 million initial payment, and the parties granted each other 10-year licenses to insulin delivery patents. The same day, shareholders elected all eight directors, approved executive pay on an advisory basis, and ratified Ernst & Young as auditor.

  • Settlement resolves disputes over the t:slim X2 pump and two Roche-related EP patents, ending pending actions in France and Germany.
  • Tandem entities will pay $36 million over five years: an $8 million initial payment, then four equal annual installments.
  • Cross-licenses of insulin delivery system patents run for 10 years from the May 21, 2025 effective date.
  • At the May 21, 2025 annual meeting, executive pay was approved with 54,337,934 for and 1,598,126 against, and shareholders chose an annual say-on-pay vote.
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.